2.16
price down icon4.00%   -0.09
after-market After Hours: 2.30 0.14 +6.48%
loading
C 4 Therapeutics Inc stock is traded at $2.16, with a volume of 929.24K. It is down -4.00% in the last 24 hours and up +51.05% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.25
Open:
$2.23
24h Volume:
929.24K
Relative Volume:
0.74
Market Cap:
$153.38M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.809
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-10.74%
1M Performance:
+51.05%
6M Performance:
-41.30%
1Y Performance:
-65.71%
1-Day Range:
Value
$2.13
$2.345
1-Week Range:
Value
$2.0703
$2.43
52-Week Range:
Value
$1.085
$7.3573

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
Name
C 4 Therapeutics Inc
Name
Phone
(617) 231-0700
Name
Address
490 ARSENAL WAY, WATERTOWN
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CCCC
C 4 Therapeutics Inc
2.16 159.77M 20.76M -132.49M -108.55M -2.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 31.87B 3.81B -644.79M -669.77M -6.24

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Equal-Weight
Jan-29-24 Upgrade JP Morgan Underweight → Neutral
Dec-13-23 Upgrade Stifel Hold → Buy
Feb-24-23 Upgrade Credit Suisse Underperform → Neutral
Feb-24-23 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade JP Morgan Overweight → Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Apr-28-22 Initiated Credit Suisse Underperform
Apr-11-22 Downgrade BofA Securities Buy → Neutral
Mar-10-22 Initiated JP Morgan Overweight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Equal Weight
Nov-23-21 Initiated BofA Securities Buy
Oct-14-21 Initiated SVB Leerink Mkt Perform
Sep-30-21 Initiated Stifel Hold
Jun-04-21 Initiated H.C. Wainwright Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Oct-28-20 Initiated UBS Buy
Oct-27-20 Initiated BMO Capital Markets Outperform
Oct-27-20 Initiated Jefferies Buy
View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

pulisher
Jul 29, 2025

New Product Launches: Will They Boost C4 Therapeutics Inc. Stock in 2025Community Strategy With High Win Rate Backtested - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

What makes C4 Therapeutics Inc. stock price move sharplySwing Trade Entry With Volume Triggers Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 21:44:21 - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Is C4 Therapeutics Inc. stock overvalued or undervaluedGet timely alerts on market opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of C4 Therapeutics Inc. stockMaximize gains with proven stock analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is C4 Therapeutics Inc. a growth stock or a value stockRecord-setting profit potential - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the latest earnings results for C4 Therapeutics Inc.Discover stocks with superior performance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy C4 Therapeutics Inc. stockInvest confidently with professional market insights - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does C4 Therapeutics Inc. generate profit in a changing economyGet daily expert analysis on top stocks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What are C4 Therapeutics Inc. company’s key revenue driversRapid-fire capital growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is C4 Therapeutics Inc. stock attracting strong analyst attentionMaximize gains with data-driven trading alerts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is C4 Therapeutics Inc. stock expected to show significant growthBuild wealth steadily with proven stock picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why C4 Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Stock Market Insights - beatles.ru

Jul 27, 2025
pulisher
Jul 26, 2025

What analysts say about C4 Therapeutics Inc. stock outlookFree Predictions - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about C4 Therapeutics Inc. stockExceptional stock performance - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is C4 Therapeutics Inc. a good long term investmentExceptional financial outcomes - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

C4 Therapeutics Inc. Stock Analysis and ForecastMarket-crushing stock picks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives C4 Therapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com

Jul 24, 2025

C 4 Therapeutics Inc Stock (CCCC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

C 4 Therapeutics Inc Stock (CCCC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Boyle Scott N
Chief Business Officer
Feb 14 '25
Sale
3.15
490
1,544
110,842
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Cap:     |  Volume (24h):